Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasm Metastasis 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 10fludarabine 7pomalidomide 5pembrolizumab 5Dexamethasone 5daratumumab 4obinutuzumab 3glofitamab 3fludarabine phosphate 3abemaciclib 3Rituximab 3Melphalan 3Immunotherapy, Adoptive 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2pirtobrutinib 2palbociclib 2cemiplimab 2blinatumomab 2Temozolomide 2Sirolimus 2Oxaliplatin 2Nivolumab 2Mesna 2Letrozole 2Injections 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Alpelisib × 30 days × Clear all
NCT04997902 2026-06-05

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡